CsA CE Shows Continued Efficacy for Dry Eye in Post-Hoc Analysis
Cyclosporine A cationic emulsion (CsA CE) 0.1% treatment continued to show superiority vs vehicle in patients with dry eye disease, according to post-hoc analyses based on data from the SANSIKA and SICCANOVE studies presented at the 2018 World Ophthalmology Congress in Barcelona.
Investigators looked at improvements in corneal fluorescein staining (CFS) scores in those treated with CsA CE vs vehicle. Among the findings:
- Overall CFS grade distribution at month 6 was significantly different between the 2 groups.
- 36% of CsA CE patients improved by ≥3 grades, vs 15% of those receiving vehicle.
- Patients receiving the medication attained CFS grade ≤1 in a median 183 days, vs 224 days for vehicle patients.
- In the combined SANSIKA + SICCANOVE contingent with severe dry eye disease, significant differences were seen favoring CsA CE for both 2- and 3-grade improvements.
Labetoulle M. Improved CFS responses in dry eye disease patients treated with cyclosporine A cationic emulsion: SICCANOVE and SANSIKA. Poster presented at: 2018 World Ophthalmology Congress; June 16-19, 2018; Barcelona, Spain.